Skip to content
    COR
    Earnings call· Mar 2025(Q2 FY25)

    Cencora Q2 FY25 earnings call COR

    May 7, 2025 Source

    Executive summary

    Cencora Q2 FY25 — Strong U.S. Performance Drives Raised Full-Year Guidance

    Cencora delivered strong Q2 FY25 results, primarily driven by robust performance in its U.S. Healthcare Solutions segment, leading to a raise in full-year adjusted EPS and operating income guidance. The company continues to leverage its pharmaceutical-centric strategy, focusing on specialty markets and expanding value-added services, despite facing headwinds in its International segment due to subdued clinical trial activity.

    Highlights

    5

    • Consolidated revenue grew 10% to $75.5 billion in Q2 FY25.

    • Adjusted diluted EPS grew 16% in Q2 FY25.

    • U.S. Healthcare Solutions segment operating income increased 23% to $1.0 billion in Q2 FY25.

    • Full-year adjusted diluted EPS guidance raised to $15.70-$15.95 from $15.30-$15.60.

    • Full-year consolidated operating income growth guidance raised to 13.5%-15.5% from 11.5%-13.5%.

    Concerns

    3

    • International Healthcare Solutions operating income declined 17% (as-reported) and 14% (constant currency) in Q2 FY25.

    • International Healthcare Solutions full-year operating income guidance lowered to down 4% to down 1% (as-reported).

    • GLP-1 sales saw a 10% sequential decline from Q1 FY25.

    Guidance & targets

    11
    CategoryTargetConfidence
    Adjusted Diluted EPS
    $15.70 to $15.95
    high materiality
    High
    Consolidated Revenue Growth
    8% to 10%
    high materiality
    Medium
    International Healthcare Solutions Segment Revenue Growth (as-reported)
    3% to 4%
    medium materiality
    Medium
    International Healthcare Solutions Segment Revenue Growth (constant currency)
    6% to 8%
    medium materiality
    Medium
    Consolidated Operating Income Growth
    13.5% to 15.5%
    high materiality
    High
    U.S. Healthcare Solutions Segment Operating Income Growth
    17.5% to 19.5%
    high materiality
    High
    International Healthcare Solutions Segment Operating Income (as-reported)
    down 4% to down 1%
    medium materiality
    Medium
    International Healthcare Solutions Segment Operating Income (constant currency)
    down 3% to flat
    medium materiality
    Medium
    Effective Income Tax Rate
    slightly below 21%
    low materiality
    High
    Diluted Weighted Average Shares Outstanding
    195 million to 195.5 million
    low materiality
    High
    Adjusted Free Cash Flow
    $2 billion to $3 billion
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    U.S. Healthcare Solutions
    Strong utilization trends, including GLP-1s, and growth in sales of specialty products to specialty physician practices and health systems. Benefited from continued uptake of biosimilars.
    Operating Income growth: 23%GLP-1 sales: $2.2 billionGLP-1 sales growth YoY: 36%GLP-1 sales sequential decline from Q1: 10%Revenue growth excluding GLP-1s: 9%COVID-19 vaccine headwind: approximately $15 million
    		$68.3 billion11%—$1.0 billion
    International Healthcare Solutions
    Decline driven by continued softness for global specialty logistics business as clinical trial activity remains subdued. Difficult comparison for European distribution due to manufacturers' price adjustments in the prior year. Solid operational performance within European distribution, particularly in 3PL, excluding price adjustments.
    Operating Income decline YoY (as-reported): 17%Operating Income decline YoY (constant currency): 14%
    		$7.2 billion1% (as-reported), 6% (constant currency)—$159 million

    Operational metrics

    9
    Consolidated Gross Profit
    $2.9 billionup 15%
    Q2 FY25

    Due to growth in the U.S. Healthcare Solutions segment.

    Consolidated Operating Expenses
    $1.7 billionup 15%
    Q2 FY25

    Focus on productivity initiatives while investing in business and operations.

    Net Interest Expense
    $104 millionincrease of $40 million versus prior year
    Q2 FY25

    Offset by repayment of senior notes that matured in March.

    Diluted Share Count
    195.1 million3% decrease compared to prior year
    Q2 FY25

    Driven by approximately $1.0 billion in opportunistic share repurchases over the past year.

    Share Repurchases
    $50 million
    February

    In concurrence with Walgreens Boots Alliance sale of shares. No further share repurchases anticipated for balance of fiscal year.

    Cash Balance
    $2 billion
    as of March 31, 2025

    Ended March with this balance.

    RCA Accounting Determination EPS Impact
    $0.14increase
    FY25

    Results in higher-than-expected EPS contribution from RCA for the fiscal year, with no impact on operating income.

    U.S. Healthcare Solutions Revenue Growth (ex-GLP-1s)
    9%
    Q2 FY25

    Calculated by excluding sales of GLP-1 products.

    Pharmacy Deserts
    30 million
    current

    Estimated number of people living in pharmacy deserts, threatening access to care.

    Industry KPIs

    9
    MetricValueDetails
    EPS16%%
    Gross margin3.86%%
    Debt leverage$3.3 billionUSD
    Tariff impactnot material
    Revenue net sales$75.5 billionUSD
    Effective tax rate20.8%%
    Cash investments balance$2 billionUSD
    Free cash flow operating cash flowslightly below $200 millionUSD
    Geographic regional revenue growth11%%

    Deals & partnerships

    2
    Retina Consultants of America (RCA)Acquisition of a management services organization (MSO) for retina specialists, expanding into value-added services.Financed with $3.3 billion in senior notes and a term loan

    Integration progress is being made. Sales from Specialty Physician Services business to RCA are now eliminated in consolidation.

    OneOncologyInvestment in an oncology management services organization (MSO).

    Viewed as a natural evolution of the specialty business, adding value-added services to the customer base.

    Risks & headwinds

    4
    Subdued clinical trial activity impacting global specialty logisticsOngoing, slower rebound than expected

    International Healthcare Solutions operating income down 17% (as-reported) and 14% (constant currency) in Q2 FY25. FY25 guidance lowered to down 4% to down 1% (as-reported).

    Mitigation: Well-positioned with services and partners to capitalize on market rebound.

    Tougher GLP-1 growth comparisonsSecond half of FY25

    GLP-1 sales saw a 10% sequential decline from Q1 FY25. Consolidated revenue growth expected at bottom end of 8%-10% range.

    Mitigation: Not explicitly stated, but implies focus on other growth drivers and mix benefits.

    Declining sales of high-priced mail order products due to biosimilar competitionSecond half of FY25

    Contributes to lower revenue growth expected in the second half of the year.

    Mitigation: These dynamics are positive for profit margins.

    Increased net interest expense from RCA acquisition financingOngoing

    Net interest expense increased $40 million year-over-year in Q2 FY25.

    Mitigation: Focus on deleveraging following the RCA acquisition; no further share repurchases anticipated for the balance of the fiscal year.

    What to watch in Q3 FY25

    4

    International Healthcare Solutions operating income

    Next quarter / H2 FY25
    CurrentDown 17% (as-reported) in Q2 FY25
    TargetRebound in demand for clinical trial and outsourced pharma services

    Why it matters

    Indicates recovery in higher-margin international businesses, which faced continued softness.

    The decline was driven by continued softness for our global specialty logistics business as clinical trial activity remains subdued.

    Q&A highlights

    7

    How will the strength in U.S. Healthcare Solutions operating income play out for the rest of the year, and what are the long-term drivers of its continuation?

    Management attributes continued strong performance to Cencora's positioning in growing specialty pharmaceutical markets, broad reach across provider types (independent pharmacies, health systems), and a growth mindset with ongoing investment in services and partnerships.

    “One is how well we're positioned in the growing parts of the pharmaceutical market. So obviously, we talk a lot about how well we're positioned in the specialty market. That is where most of the innovation in the pharmaceutical industry is happening.”

    asked by Elizabeth Anderson · answered by Robert Mauch

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Focus on Specialty and End-to-End Solutions

    Cencora emphasizes its pharmaceutical-centric strategy, expanding capabilities in key markets to support innovation and access. The company leverages extensive data for actionable insights, enhancing efficiency and innovation, particularly in specialty medications. This approach positions Cencora as a leading end-to-end healthcare solutions provider, supporting pharmaceutical commercialization across the ecosystem.

    02

    Deepening Customer Partnerships and Market Insights

    The company actively engages with industry stakeholders, including independent pharmacies, oncology practices, and biopharma companies, to understand and anticipate their needs. Through advanced analytics and its Good Neighbor Pharmacy network, Cencora provides insights to pharmacies to identify new business opportunities and address care gaps. Dispensing insights are also used to inform biopharma partners on key product trends, such as bladder cancer treatment paradigms.

    03

    Global Leadership in Specialty Medications

    Cencora is strengthening its global leadership in specialty by integrating U.S. and European 3PL businesses, creating a unified network for multinational reach and successful product launches. The company is increasing capabilities in key European markets to enhance pharmaceutical logistics. In the U.S., offerings are being deepened across provider channels, including health systems, to support the rising use of specialty medications and provide comprehensive patient-centric care.

    04

    Strong U.S. Performance and GLP-1 Dynamics

    The U.S. Healthcare Solutions segment delivered strong performance, driven by utilization trends, including GLP-1 products, and growth in specialty sales to physician practices and health systems. While GLP-1 sales contributed significantly, increasing $2.2 billion or 36% year-over-year, they saw a 10% sequential decline from Q1. The company anticipates tougher GLP-1 growth comparisons and declining sales of high-priced mail-order products due to biosimilar competition in the second half of the year, which are expected to impact revenue growth but positively affect profit margins.

    05

    International Segment Headwinds

    The International Healthcare Solutions segment experienced a decline in operating income due to continued softness in global specialty logistics, impacted by subdued clinical trial activity, and a difficult prior-year comparison in European distribution. The rebound in demand for clinical trial and outsourced pharma services has been slower than expected, leading to a reduction in the segment's full-year operating income guidance.

    06

    RCA Acquisition and Accounting Determination

    The acquisition of Retina Consultants of America (RCA) significantly contributed to consolidated gross profit and operating margin due to its higher-margin business model. An accounting determination classified the approximately 15% equity owned by RCA physicians and management as a contingent liability rather than a noncontrolling interest. This resulted in a higher-than-expected EPS contribution from RCA for FY25, specifically $0.14 of the EPS guidance increase, without impacting operating income results or guidance.

    AI-generated summary of the company’s earnings call. Not investment advice.